Evaluating Drug Effects in the Post-Vioxx World
- 9 May 2006
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (18) , 2173-2176
- https://doi.org/10.1161/circulationaha.106.625749
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Clinical Trials in the Wake of VioxxCirculation, 2006
- Reform of Drug Regulation — Beyond an Independent Drug-Safety BoardNew England Journal of Medicine, 2006
- FDA Standards — Good Enough for Government Work?New England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug ReactionsJAMA, 2004
- Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with ArthritisNew England Journal of Medicine, 2002
- Representation of Elderly Persons and Women in Published Randomized Trials of Acute Coronary SyndromesJAMA, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Evaluating Drugs after Their Approval for Clinical UseNew England Journal of Medicine, 1993